|Day's Range||27.03 - 27.17|
|52 Week Range||19.67 - 27.17|
|PE Ratio (TTM)||86.99|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Boston Scientific Corporation (BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study.
Guru's largest 1st-quarter trades
Companies are winning over the SEC in their use of unofficial accounting figures, a year after a crackdown on the practice.